PMID- 24419410
OWN - NLM
STAT- MEDLINE
DCOM- 20140916
LR  - 20201226
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 9
IP  - 2
DP  - 2014 Feb
TI  - Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
PG  - 144-53
LID - 10.1097/JTO.0000000000000074 [doi]
AB  - Despite current therapeutic options metastatic non- small-cell lung cancer 
      (NSCLC) remains incurable. Targeted therapies have opened new opportunities for 
      several molecular subtypes, but virtually all patients treated will ultimately 
      develop progressive disease by treatment resistance. Recent clinical trials have 
      shown that immune-checkpoint blockade can result in striking and durable 
      responses in metastatic NSCLC. These impressive results are yet to be confirmed 
      in following trials; nonetheless, NSCLC therapeutic strategies will most likely 
      need to integrate immune-checkpoint inhibitors in the near future. Interestingly, 
      conventional therapies are capable of modulating the immune system and can 
      therefore interact directly or indirectly with immunotherapies. This suggests 
      that some combinations might have synergistic activity and lead to improved 
      efficacy. Conventional and targeted therapies can induce rapid tumor lysis, and 
      immune-checkpoint blockade can then help to induce a sustained immune-mediated 
      tumor control. Moreover, the distinctive toxicity profile associated with 
      immune-checkpoint modulators makes them good candidates for combination 
      strategies. Here we summarize the results of immune-checkpoints trials in NSCLC, 
      and also report how current therapeutic options can modulate the immune system. 
      We provide a rationale and identify potential challenges for immune-checkpoint 
      blockade combinations with conventional therapeutics in NSCLC.
FAU - Champiat, Stephane
AU  - Champiat S
AD  - *SITEP (Service d'Innovations Therapeutiques Precoces), Department of Medicine, 
      Gustave Roussy, daggerInstitut Gustave Roussy, University Paris Sud, Villejuif, 
      France; double daggerLombardi Comprehensive Cancer Center, Georgetown University, Washington, 
      District of Columbia;  section signThoracic Multidisciplinary Committee, Gustave Roussy, 
      University Paris Sud, Villejuif, France; and  ||Department of Medical Oncology, 
      University of Athens School of Medicine, Athens, Greece.
FAU - Ileana, Ecaterina
AU  - Ileana E
FAU - Giaccone, Giuseppe
AU  - Giaccone G
FAU - Besse, Benjamin
AU  - Besse B
FAU - Mountzios, Giannis
AU  - Mountzios G
FAU - Eggermont, Alexander
AU  - Eggermont A
FAU - Soria, Jean-Charles
AU  - Soria JC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (CTLA4 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors
MH  - CTLA-4 Antigen/*antagonists & inhibitors
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/immunology
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
EDAT- 2014/01/15 06:00
MHDA- 2014/09/17 06:00
CRDT- 2014/01/15 06:00
PHST- 2014/01/15 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2014/09/17 06:00 [medline]
AID - S1556-0864(15)30183-0 [pii]
AID - 10.1097/JTO.0000000000000074 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2014 Feb;9(2):144-53. doi: 10.1097/JTO.0000000000000074.